Madrigal Pharmaceuticals Stock Earnings Reports

Madrigal reported a strong start to 2026 driven by continuing Rezdiffra commercial momentum: Q1 net sales were $311.3M (up 127% YoY) and active patients on therapy exceeded 42,250 (2.5x vs Q1 2025). Rezdiffra reached blockbuster status with >$1.1B trailing-12-month net sales, but penetration and diagnosis remain low (addressable U.S. F2/F3 patient pool grew ~50% to ~460,000 and diagnosis rate is ~10%), implying substantial runway. Key clinical priorities are an event-driven F4C outcomes trial (readout expected in 2027) that could expand labeling into well‑compensated cirrhosis and two Phase III outcomes programs through 2028. Madrigal expanded its pipeline to >10 programs, adding ARO‑PNPLA3 (a clinical‑stage siRNA targeting PNPLA3 homozygotes) and advancing combination strategies (including GLP‑1 and other modalities) with the goal of building Rezdiffra‑anchored regimens. Financials reflect launch investments and BD activity: gross‑to‑net guidance mid‑ to high‑30s% for 2026, R&D and SG&A rising (R&D impacted by a $54.3M one‑time BD charge in Q1 with further $25M ARO‑PNPLA3 payment expected in Q2), Q1 net loss $94.4M, and cash resources of ~$818M to fund launch and pipeline. Management reiterates focus on evidence generation, disciplined BD, efficient development, and preparing for eventual profitability (not expected in 2026).